Table 2.
Hepatocellular carcinoma prediction risk scores for chronic hepatitis B patients
|
Risk scores
|
Cohort: Patients/ratio of cirrhosis
|
Study population
|
Antiviral treatment
|
Variables
|
External validation
|
| GAG-HCC (Yuen et al[26], 2009) | Training: 820/15%; Validation: - | Asian (Hong Kong) | No | Age; Gender; HBV-DNA; Cirrhosis | Asian, Caucasian |
| CU-HCC (Wong et al[27], 2010) | Training: 1055/38%; Validation: 428/16% | Asian (Hong Kong) | No | Age; Albumin; Bilirubin; HBV-DNA; Radiologic cirrhosis | Asian, Caucasian |
| REACH-B (Yang et al[29], 2011) | Training: 3584/0; Validation: 1505/18% | Asian (Taiwan) | No | Age; Gender; ALT; HBeAg status; HBV-DNA concentration | Asian, Caucasian |
| REACH-BII(Lee et al[30], 2013) | Training: 2227/0; Validation: 1113/0 | Asian (Taiwan) | No | Age; Gender; ALT; HBeAg/HBV-DNA/HBsAg/Genotype status | - (Internal only) |
| mREACH-B (Lee et al[31], 2014) | Training: 192/46.9%; Validation: - | Asian (South Korea) | ETV | Gender; ALT; HBeAg status; LSM value | Asian |
| LSM-HCC (Wong et al[33], 2014) | Training: 1035/32%; Validation: 520/31% | Asian (Hong Kong) | No | Age; Albumin; HBV-DNA concentration; LSM value | Asian |
| RWS-HCC (Poh et al[34], 2016) | Training: 583/13.7%; Validation: 3353/NA | Asian (Singapore) | No | Age; Sex; Cirrhosis; AFP | Asian, Caucasian |
| PAGE-B (Papatheodoridis et al[39], 2016) | Training: 1325/20%; Validation: 490/48% | Caucasians (Europe) | ETV/TDF | Age; Gender; Platelet count | Asian, Caucasian |
| mPAGE-B (Kim et al[42], 2018) | Training: 2001/19%; Validation: 1000/20% | Asian (South Korea) | ETV/TDF | Age; Gender; Platelet count; Albumin | Asian |
| HCC-RESCUE (Sohn et al[44], 2017) | Training: 990/39%; Validation: 1071/35% | Asian (South Korea) | ETV | Age; Gender; Cirrhosis | Asian |
| APA-B (Chen et al[45], 2017) | Training: 883/36%; Validation: 442/236% | Asian (Taiwan) | ETV | Age; Platelet; AFP | Asian |
| HCC-ESC (Fung et al[35], 2018) | Training: 723/NA; Validation: - | Asian (Hong Kong) | No | Age; Gender; Cirrhosis; Hypoalbuminemia; HBV-DNA; ALT | - |
| CAMD (Hsu et al[46], 2018) | Training: 23851/26.4%; Validation: 19321/7.1% | Asian (Taiwan) | ETV/TDF | Age; Gender; Diabetes; Cirrhosis | Asian |
| AGED (Fan et al[36], 2019) | Training: 628/0%; Validation: 1663/0% | Asian (China) | No | Age; Gender; HBeAg status; HBV-DNA | - (Internal only) |
| AASL-HCC (Yu et al[47], 2019) | Training: 944/39%; Validation: 298/39% | Asian (South Korea) | ETV/TDF | Age; Gender; Albumin; Cirrhosis | Asian |
| REAL-B (Yang et al[48], 2020) | Training: 5365/20.2%; Validation: 2683/22.1% | Asian (Multiethnicity) | Yes (not specified) | Age; Gender; Alcohol use; Diabetes; Platelet count; Cirrhosis; AFP | - (Internal only) |
| HCC-ESCAVT (Lim et al[49], 2020) | Training: 769/41.5%; Validation: 1061/26.1% | Asian (South Korea) | ETV/TDF | Gender; Cirrhosis; Fibrosis-4 index | - (Internal only) |
GAG-HCC: The guide with age, gender, hepatitis B virus DNA, core promoter mutations, and cirrhosis risk score; CU-HCC: Chinese University-hepatocellular carcinoma risk score; REACH-B: The risk estimation for hepatocellular carcinoma in chronic hepatitis B score; RWS: Real-world score; APA-B: Age, platelet, alpha-fetoprotein-B score; CAMD: Cirrhosis, age, male gender, diabetes score; AFP: Alpha-fetoprotein, ALT: Alanine aminotransferase, HBeAg: Hepatitis B e Antigen, HBV: Hepatitis B virus, LSM: Liver stiffness measurement.